OncoSec reports preliminary Phase I data for ImmunoPulse IL-12 in TNBC

OncoSec Medical Inc. (NASDAQ:ONCS) reported preliminary data from two evaluable heavily pretreated patients with metastatic triple-negative breast cancer (TNBC) in the Phase I OMS-I140 trial showing that a single cycle of intratumoral ImmunoPulse IL-12 (OMS ElectroImmunotherapy, DNA IL-12) followed by treatment with anti-PD-1 mAb Opdivo nivolumab as a single agent led to "robust objective responses in ImmunoPulse IL-12 treated and untreated lesions." OncoSec did not disclose details, but said additional data will be presented at an upcoming medical meeting.

The open-label, U.S. trial is evaluating changes in the proportion of intratumoral lymphocyte subsets and NanoString-based gene expression as its primary endpoints. Secondary endpoints include safety, antitumor activity and detection of plasmid IL-12 in untreated lesions. Five patients have been treated in the trial, which is expected to enroll about 10 patients...